Try our Advanced Search for more refined results

J&J Closes $885M Alzheimer's Drug Deal With Elan

By Erin Coe (September 17, 2009, 2:38 PM EDT) -- Johnson & Johnson has completed an $885 million deal to own a stake in Elan Corp. and gain rights to the Irish biotechnology company's Alzheimer's disease treatment program, now that Elan has cured its breach of contract with Biogen Idec Inc. to make way for the new deal....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!